Pretreatment with metformin prevents microcystin-LR-induced tau hyperphosphorylation via mTOR-dependent PP2A and GSK-3β activation

Environ Toxicol. 2021 Dec;36(12):2414-2425. doi: 10.1002/tox.23354. Epub 2021 Aug 25.

Abstract

Microcystin-leucine-arginine (MC-LR) is a toxin secreted by freshwater cyanobacteria that is considered a potential environmental risk factor for Alzheimer's disease (AD). A previous study indicated that tau protein hyperphosphorylation via protein phosphatase 2A (PP2A) and GSK-3β inhibition was the mechanism by which MC-LR induces neurotoxicity; however, how MC-LR-induced neurotoxicity can be effectively prevented remains unclear. In this study, the reversal effect of metformin on MC-LR-induced neurotoxicity was investigated. The results showed that metformin effectively prevented tau hyperphosphorylation at Ser202 caused by MC-LR through PP2A and GSK-3b activity. The effect of metformin on PP2A activity was dependent on the inhibition of mTOR in MC-LR-treated SH-SY5Y cells. Metformin prevented spatial memory deficits in rats caused by intrahippocampal MC-LR administration. In sum, the results suggested that metformin can ameliorate the MC-LR-induced AD-like phenotype by preventing tau phosphorylation at Ser202, which was mainly mediated by mTOR-dependent PP2A and GSK-3β activation.

Keywords: GSK-3β; PP2A; metformin; microcystin-LR; tau phosphorylation.

MeSH terms

  • Animals
  • Glycogen Synthase Kinase 3 beta
  • Marine Toxins
  • Metformin* / pharmacology
  • Microcystins / toxicity
  • Phosphorylation
  • Protein Phosphatase 2 / metabolism
  • Rats
  • TOR Serine-Threonine Kinases
  • tau Proteins* / metabolism

Substances

  • Marine Toxins
  • Microcystins
  • tau Proteins
  • Metformin
  • mTOR protein, rat
  • Glycogen Synthase Kinase 3 beta
  • TOR Serine-Threonine Kinases
  • Protein Phosphatase 2
  • cyanoginosin LR